RDY · Categories · Offerings
RDY - Public offerings
Dr. Reddy's Laboratories Ltd (RDY) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for RDY
- Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial ResultsCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the first quarter ended March 31, 2023, and provided a clinical and business update. Q1 2023 and Recent Highlights (Unaudited) Announced positive results from a proof-of-concept, open-label academic clinical study of COYA 302 in Amyotrophic Lateral Sclerosis (ALS) illustrating halting of disease progression at 24 weeks with minimal decline at 48 weeks. Study data were presented at the 2023 Muscle Dystrophy Association Conference; Announc
- Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial ResultsCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells (Tregs) function, today announced its financial results for fiscal year ended December 31, 2022, and provided a clinical and business update. FY 2022 and Early 2023 Highlights In March 2023, the Company announced positive results from a proof-of-concept, open-label academic clinical study of COYA 302 in Amyotrophic Lateral Sclerosis (ALS). Study data were presented at the 2023 Muscle Dystrophy Association Conference; In March 2023, Coya entered into a worldwide agreement with Dr. Reddy's Labora